Quick Summary:
In the rapidly evolving landscape of healthcare, the global market for Endometrial Cancer Treatment is witnessing steady growth. Our detailed market research report presents an in-depth exploration of this thriving market's size, projected to reach $41.6 billion by 2030 from $28.3 billion in 2022. It specifically notes the growth potential of segments like Chemotherapy, poised to touch $28.2 billion by the close of this period.
This report also provides a well-rounded market overview inclusive of diverse geographic segments. The U.S. is firmly leading the charge with an estimate of $8.5 billion in 2022, but China closely follows with its own forecast of $7.4 billion by 2030. Key markets like Germany, Japan, and Canada also present strong growth outlooks. The analysis further includes data on market leaders like Abbott Laboratories, Sanofi SA, and Siemens Healthineers. Alongside comprehensive market coverage, the report offers special insights on impactful global events, competitive market shares, as well as archived research and bespoke updates for a comprehensive understanding of this booming marketplace.
Global Endometrial Cancer Treatment Market to Reach $41.6 Billion by 2030
The global market for Endometrial Cancer Treatment estimated at US$28.3 Billion in the year 2022, is projected to reach a revised size of US$41.6 Billion by 2030, growing at a CAGR of 4.9% over the analysis period 2022-2030. Chemotherapy, one of the segments analyzed in the report, is projected to record 4.7% CAGR and reach US$28.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Hormone therapy segment is readjusted to a revised 5.5% CAGR for the next 8-year period.
The U.S. Market is Estimated at $8.5 Billion, While China is Forecast to Grow at 4.8% CAGR
The Endometrial Cancer Treatment market in the U.S. is estimated at US$8.5 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$7.4 Billion by the year 2030 trailing a CAGR of 4.8% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.5% and 4.1% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.Select Competitors (Total 38 Featured) -
- Abbott Laboratories, Inc.
- ARIAD Pharmaceuticals, Inc.
- Becton, Dickinson and Company
- F. Hoffmann-La Roche AG
- GlaxoSmithKline PLC
- Merck & Co., Inc.
- Novartis AG
- Sanofi SA
- Siemens Healthineers
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
What is the estimated value of the Global Market for Endometrial Cancer Treatment?
What is the growth rate of the Global Market for Endometrial Cancer Treatment?
What is the forecasted size of the Global Market for Endometrial Cancer Treatment?
Who are the key companies in the Global Market for Endometrial Cancer Treatment?
| Report Attribute | Details |
|---|---|
| No. of Pages | 192 |
| Published | December 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 28.3 Billion |
| Forecasted Market Value ( USD | $ 41.6 Billion |
| Compound Annual Growth Rate | 4.9% |
| Regions Covered | Global |
Table of Contents
Companies Mentioned
A selection of companies mentioned in this report includes:
- Abbott Laboratories, Inc.
- ARIAD Pharmaceuticals, Inc.
- Becton, Dickinson and Company
- F. Hoffmann-La Roche AG
- GlaxoSmithKline PLC
- Merck & Co., Inc.
- Novartis AG
- Sanofi SA
- Siemens Healthineers
